MyProstateScore for Risk Stratification in Men
"Explore the validation of MyProstateScore (MPS) for risk stratification in men with previous negative biopsies, highlighting thresholds and challenges. Learn about the efficacy and implications for patient care. Further research is essential to enhance understanding and integration with mpMRI."
Uploaded on | 0 Views
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author. If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.
E N D
Presentation Transcript
Use of the MyProstateScore (MPS) for risk stratification in men with a previous negative biopsy: Initial validation of a straightforward testing approach Michael Sessine, B.S. University of Michigan Medical School
MPS Background Continuous scale from 0 (very unlikely to detect GG 2 cancer) to 100 Validation study 1,525 biopsy-na ve men MPS 10 yielded 98% negative predictive value (NPV) and 97% sensitivity for GG 2 cancer N = 422 men with prior negative biopsy in validation and training cohorts Tomlins. Eur. Urol. 2016; 70: 45 53. Tosoian. J Urol. 2021; 205(3):732-739.
Prior Negative Population Unique Challenges Rule-out high-risk disease More favorable risk profiles and pathology at the time of prostatectomy PSA changes meriting biopsy are poorly defined and less reliable Rule-in MRI or biopsy ElShafei. J Urol. 2016;195(6):1767-1772. Tan. J. Urol. 2008; 180: 1325 1329. Blute. Nat. Rev. Urol. 2015; 12: 435 444.
Results N(%) unnecessary bx avoided N (%) GG 2 diagnoses missed N (%) bx avoided Sn Sp NPV PPV Validation (n=268) MPS 15 (n=55) MPS 40 (n=179) 100% 23% 100% 12% 55 (21%) 55 (23%) 0 (0%) 179 (67%) 68% 70% 95% 19% 171 (70%) 8 (32%)
Take Home Points Prior negative population presents unique challenges that requires consideration of rule-in and rule- out thresholds MPS of 15 and 40 are reasonable thresholds to guide decision making for patients with a previous negative biopsy Further studies needed to better understand the concurrent use of mpMRI with MPS Limitations: Validation cohort size, Pre-MRI era data
